Management of patients with metastatic teratoma with malignant somatic transformation

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose of review The purpose of this review is to examine the historical context alongside contemporary studies in order to provide the most current recommendations for the management of patients with metastatic teratoma with malignant somatic transformation (MST). Recent findings The main themes in the recent literature covered herein include prognostic features, the management of early-stage disease, recommended chemotherapeutic and surgical strategies as well as recognized patterns of late relapse. Summary Recent literature, combined with a significant contribution from historical studies, suggests that while MST is uncommon, its aggressive nature coupled with its resistance with traditional germ cell tumor chemotherapies makes it very difficult to manage. The key message is that surgery is recommended in all resectable MST from primary retroperitoneal lymph node dissection for clinical stage I, to radical removal of disease after chemotherapy and when chemotherapy fails. In advanced cases with documented spread of the transformed histologic subtype, systemic therapies targeted to the identified tumor type should be considered.

Original languageEnglish (US)
Pages (from-to)469-473
Number of pages5
JournalCurrent Opinion in Urology
Volume28
Issue number5
DOIs
StatePublished - Jan 1 2018

Fingerprint

Teratoma
Drug Therapy
Germ Cell and Embryonal Neoplasms
Lymph Node Excision
Recurrence
Neoplasms
Therapeutics

Keywords

  • Malignant somatic transformation
  • Teratoma
  • Testicular neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Management of patients with metastatic teratoma with malignant somatic transformation. / Speir, Ryan; Cary, K. Clinton; Foster, Richard; Masterson, Timothy.

In: Current Opinion in Urology, Vol. 28, No. 5, 01.01.2018, p. 469-473.

Research output: Contribution to journalArticle

@article{cae72b7a1dd54a09958dfabe6a6c197a,
title = "Management of patients with metastatic teratoma with malignant somatic transformation",
abstract = "Purpose of review The purpose of this review is to examine the historical context alongside contemporary studies in order to provide the most current recommendations for the management of patients with metastatic teratoma with malignant somatic transformation (MST). Recent findings The main themes in the recent literature covered herein include prognostic features, the management of early-stage disease, recommended chemotherapeutic and surgical strategies as well as recognized patterns of late relapse. Summary Recent literature, combined with a significant contribution from historical studies, suggests that while MST is uncommon, its aggressive nature coupled with its resistance with traditional germ cell tumor chemotherapies makes it very difficult to manage. The key message is that surgery is recommended in all resectable MST from primary retroperitoneal lymph node dissection for clinical stage I, to radical removal of disease after chemotherapy and when chemotherapy fails. In advanced cases with documented spread of the transformed histologic subtype, systemic therapies targeted to the identified tumor type should be considered.",
keywords = "Malignant somatic transformation, Teratoma, Testicular neoplasms",
author = "Ryan Speir and Cary, {K. Clinton} and Richard Foster and Timothy Masterson",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/MOU.0000000000000528",
language = "English (US)",
volume = "28",
pages = "469--473",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Management of patients with metastatic teratoma with malignant somatic transformation

AU - Speir, Ryan

AU - Cary, K. Clinton

AU - Foster, Richard

AU - Masterson, Timothy

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose of review The purpose of this review is to examine the historical context alongside contemporary studies in order to provide the most current recommendations for the management of patients with metastatic teratoma with malignant somatic transformation (MST). Recent findings The main themes in the recent literature covered herein include prognostic features, the management of early-stage disease, recommended chemotherapeutic and surgical strategies as well as recognized patterns of late relapse. Summary Recent literature, combined with a significant contribution from historical studies, suggests that while MST is uncommon, its aggressive nature coupled with its resistance with traditional germ cell tumor chemotherapies makes it very difficult to manage. The key message is that surgery is recommended in all resectable MST from primary retroperitoneal lymph node dissection for clinical stage I, to radical removal of disease after chemotherapy and when chemotherapy fails. In advanced cases with documented spread of the transformed histologic subtype, systemic therapies targeted to the identified tumor type should be considered.

AB - Purpose of review The purpose of this review is to examine the historical context alongside contemporary studies in order to provide the most current recommendations for the management of patients with metastatic teratoma with malignant somatic transformation (MST). Recent findings The main themes in the recent literature covered herein include prognostic features, the management of early-stage disease, recommended chemotherapeutic and surgical strategies as well as recognized patterns of late relapse. Summary Recent literature, combined with a significant contribution from historical studies, suggests that while MST is uncommon, its aggressive nature coupled with its resistance with traditional germ cell tumor chemotherapies makes it very difficult to manage. The key message is that surgery is recommended in all resectable MST from primary retroperitoneal lymph node dissection for clinical stage I, to radical removal of disease after chemotherapy and when chemotherapy fails. In advanced cases with documented spread of the transformed histologic subtype, systemic therapies targeted to the identified tumor type should be considered.

KW - Malignant somatic transformation

KW - Teratoma

KW - Testicular neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85056498164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056498164&partnerID=8YFLogxK

U2 - 10.1097/MOU.0000000000000528

DO - 10.1097/MOU.0000000000000528

M3 - Article

C2 - 29939859

AN - SCOPUS:85056498164

VL - 28

SP - 469

EP - 473

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 5

ER -